SPECIALIZED PRESS August 3, 2021 Not intended for U.S. and UK MediaBayer’s investigational P2X3 antagonist meets primary efficacy endpoint and shows favorable safety and tolerability profileRead more
August 2, 2021 Bayer selects 100 youth leaders from around the world to help “Feed a Hungry Planet” at the company’s 5th biennial Youth Ag SummitRead more
July 26, 2021 Bayer announces Prof. Dr. Dominik Ruettinger as new Head of Research and Early Development for OncologyRead more
SPECIALIZED PRESS July 21, 2021 Not intended for U.S. and UK MediaBayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EURead more
July 19, 2021 BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson’s DiseaseRead more
SPECIALIZED PRESS July 9, 2021 Not intended for U.S. and UK MediaU.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetesRead more
.jpg)
